U.S. regulators approved Lilly's once-daily oral Foundayo on April 1, 2026. Lilly's second-quarter release listed $23.0 billion of revenue, 48% growth, and full-year revenue guidance of $85 billion to $87 billion. Novo Nordisk announced a January 5 launch for the Wegovy pill, while Lilly later described Foundayo as the only weight-loss GLP-1 pill that may be taken at any time without food or water restrictions.S1S2S3S4
Oral delivery changes the funnel
Investors should separate patient convenience from durable commercial adoption. A pill could widen interest, but payer access, persistence, safety, and net pricing may determine whether initial demand becomes recurring use.
Prescriptions need context
Prescription estimates may offer an early directional signal, yet sampling, channel stocking, and revisions could distort a young launch curve. A better scorecard would compare starts with refills, coverage, and net economics.
Capacity and safety shape the market
Investors should weigh manufacturing capacity alongside authenticity and safety. Supply expansion could support access, while counterfeit or unapproved sellers may raise patient risk and complicate market interpretation.
The first rejection
The bullish case could strengthen if persistence broadens, payer access improves, and margins scale. It could weaken if discontinuation, restrictions, safety concerns, or heavy discounting prevent early starts from becoming recurring demand.
What to watch next
Readers should track prescription starts, refill persistence, formulary access, capacity expansion, net pricing, and safety communications. Clinical decisions should remain with qualified health professionals.
Evidence ledger